WallStreetZenWallStreetZen

NASDAQ: CLLS
Cellectis Sa Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CLLS

Based on 2 analysts offering 12 month price targets for Cellectis Sa.
Min Forecast
$6.00+203.03%
Avg Forecast
$8.00+304.04%
Max Forecast
$10.00+405.05%

Should I buy or sell CLLS stock?

Based on 2 analysts offering ratings for Cellectis Sa.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CLLS stock forecasts and price targets.

CLLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-12
lockedlocked$00.00+00.00%2024-05-31

1 of 1

Forecast return on equity

Is CLLS forecast to generate an efficient return?
Company
-22.23%
Industry
-762.05%
Market
49.3%
CLLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLLS forecast to generate an efficient return on assets?
Company
-8.11%
Industry
26.89%
CLLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLLS earnings per share forecast

What is CLLS's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
-$0.51
Avg 3 year Forecast
-$0.01

CLLS revenue forecast

What is CLLS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$19.0M-3.23%
Avg 2 year Forecast
$60.0M+205.58%
Avg 3 year Forecast
$122.8M+525.41%
CLLS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CLLS revenue growth forecast

How is CLLS forecast to perform vs Biotechnology companies and vs the US market?
Company
82.41%
Industry
36.05%
Market
9.61%
CLLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CLLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CLLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLLS$1.98$8.00+304.04%Buy
KYTX$4.61$20.00+333.84%Buy
AMLX$2.94$4.50+53.06%Hold
BDTX$3.66$15.50+323.50%Strong Buy
PYXS$3.51$8.50+142.17%Strong Buy
View Top Biotech Stocks

Cellectis Sa Stock Forecast FAQ

Is Cellectis Sa Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CLLS) stock is to Buy CLLS stock.

Out of 2 analysts, 0 (0%) are recommending CLLS as a Strong Buy, 2 (100%) are recommending CLLS as a Buy, 0 (0%) are recommending CLLS as a Hold, 0 (0%) are recommending CLLS as a Sell, and 0 (0%) are recommending CLLS as a Strong Sell.

If you're new to stock investing, here's how to buy Cellectis Sa stock.

What is CLLS's earnings growth forecast for 2024-2026?

(NASDAQ: CLLS) Cellectis Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.

Cellectis Sa's earnings in 2024 is -$79,971,000.On average, 1 Wall Street analyst forecast CLLS's earnings for 2024 to be -$54,050,563, with the lowest CLLS earnings forecast at -$54,050,563, and the highest CLLS earnings forecast at -$54,050,563. On average, 1 Wall Street analyst forecast CLLS's earnings for 2025 to be -$51,047,754, with the lowest CLLS earnings forecast at -$51,047,754, and the highest CLLS earnings forecast at -$51,047,754.

In 2026, CLLS is forecast to generate -$1,000,936 in earnings, with the lowest earnings forecast at -$1,000,936 and the highest earnings forecast at -$1,000,936.

What is CLLS's revenue growth forecast for 2024-2026?

(NASDAQ: CLLS) Cellectis Sa's forecast annual revenue growth rate of 82.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.61%.

Cellectis Sa's revenue in 2024 is $19,635,000.On average, 1 Wall Street analysts forecast CLLS's revenue for 2024 to be $1,901,779,065, with the lowest CLLS revenue forecast at $1,901,779,065, and the highest CLLS revenue forecast at $1,901,779,065. On average, 1 Wall Street analysts forecast CLLS's revenue for 2025 to be $6,005,618,100, with the lowest CLLS revenue forecast at $6,005,618,100, and the highest CLLS revenue forecast at $6,005,618,100.

In 2026, CLLS is forecast to generate $12,291,498,378 in revenue, with the lowest revenue forecast at $12,291,498,378 and the highest revenue forecast at $12,291,498,378.

What is CLLS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CLLS) forecast ROA is -8.11%, which is lower than the forecast US Biotechnology industry average of 26.89%.

What is CLLS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CLLS price target, the average CLLS price target is $8.00, with the highest CLLS stock price forecast at $10.00 and the lowest CLLS stock price forecast at $6.00.

On average, Wall Street analysts predict that Cellectis Sa's share price could reach $8.00 by Jun 12, 2025. The average Cellectis Sa stock price prediction forecasts a potential upside of 304.04% from the current CLLS share price of $1.98.

What is CLLS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CLLS) Cellectis Sa's current Earnings Per Share (EPS) is -$1.25. On average, analysts forecast that CLLS's EPS will be -$0.54 for 2024, with the lowest EPS forecast at -$0.54, and the highest EPS forecast at -$0.54. On average, analysts forecast that CLLS's EPS will be -$0.51 for 2025, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.51. In 2026, CLLS's EPS is forecast to hit -$0.01 (min: -$0.01, max: -$0.01).

What is CLLS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CLLS) forecast ROE is -22.23%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.